Creating a new targeted treatment for prostate cancer
Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate Cancer
This study is testing a new treatment for advanced prostate cancer that aims to deliver a powerful cancer-fighting drug directly to the cancer cells, which could help improve results and lessen side effects for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cancer Targeted Technology, LLC NIH-funded |
| Lab location | 1 site (Woodinville, United States) |
| Project ID | NIH-10910547 on NIH RePORTER |
What this research studies
This research focuses on developing a novel small molecule prodrug that targets prostate-specific membrane antigen (PSMA) to treat metastatic castration-resistant prostate cancer (mCRPC). The approach involves conjugating a potent cancer-fighting agent, monomethyl auristatin E (MMAE), to a targeting molecule that specifically binds to cancer cells, minimizing damage to healthy cells. By enhancing the delivery of the drug directly to the cancer cells, this method aims to improve treatment efficacy while reducing side effects. Patients may have the opportunity to participate in clinical trials evaluating this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who have limited treatment options.
Not a fit: Patients with early-stage prostate cancer or those who do not express the PSMA biomarker may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and less toxic treatment option for patients with advanced prostate cancer.
How similar studies have performed: While there have been successful applications of antibody-drug conjugates in other cancers, this specific approach using small molecule drug conjugates for mCRPC is relatively novel.
Where this research is happening
Woodinville, United States
- Cancer Targeted Technology, LLC — Woodinville, United States (Active)
Researchers
- Principal investigator: Langton-Webster, Beatrice — Cancer Targeted Technology, LLC
- Study coordinator: Langton-Webster, Beatrice
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.